Catalyst plans early 2015 rolling NDA on Firdapse Phase III
This article was originally published in Scrip
Executive Summary
Catalyst Pharmaceuticals plans to initiate a rolling new drug application (NDA) for Firdapse in early 2015, pending pre-NDA discussions with the US FDA, based on positive Phase III results in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).